AI in Drug Development: Hype or Reality?

This discussion between VeriSIM Life and experts at Pfizer, Bayer and Janssen explores how adopting AI and deep technology to the R&D process reduces costs and accelerates time to market whilst maintaining safety.

Key themes include:

• Identifying the most common barriers preventing the successful adoption of AI initiatives for drug development in small and large organizations

• Comparing the challenges with applying AI to determine safety and efficacy: Small molecule vs. large molecule candidates

• Understanding how general and deterministic systems approach PK/PD/E predictions differently: What are the impacts?

• AI adoption and the impacts of user interfaces (UI and UX) on different user groups

• Overcoming data capture, accessibility and analytic challenges: Ensuring availability of accurate, usable data for generation and prediction